← All companies ← MMSI Manual MNR → ← MIRM Pharmaceuticals MRK →
MNKD, MannKind Corporation
We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions.
With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.
Our cardiometabolic business is currently comprised of three commercial products: Afrezza (insulin human) Inhalation Powder; Furoscix (furosemide injection); and the V-Go wearable insulin delivery device: Afrezza is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes.
The business
What it sells, where the money comes from, the kind of company it is.
Next report By 11/8 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~37 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- What it is
- Revenue is led by Royalty (37%) and Products (33%), with 2 more lines behind.
- Situation
- Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has reached 38% at its best but run negative through the cycle (median −62%) on a 81% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Stock-based pay runs about 10% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 10-K →Revenue spreads across 5 lines, the largest Royalty at 37%.
- Royalty37%$128M
- Products33%$114M
- License and Service31%$107M
- Services1%$4M
- Manufacturing Services0%$2M
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $175M | $12M | $28M | $63M | $65M | $75M | $100M | $199M | $286M | $349M | $394M | RevenueRevenue |
| — | ($5M) | $8M | $43M | $50M | $59M | $84M | — | — | — | — | Gross profitGross prof. |
| — | −47% | 30% | 68% | 77% | 78% | 84% | — | — | — | — | Gross marginGross mgn |
| 27% | 638% | 286% | 118% | 91% | 103% | 92% | 47% | 33% | 41% | 51% | SG&A / revenueSG&A/rev |
| 9% | 120% | 31% | 11% | 10% | 16% | 20% | 16% | 16% | 19% | 20% | R&D / revenueR&D/rev |
| $67M | ($108M) | ($77M) | ($45M) | ($48M) | ($47M) | ($64M) | $9M | $73M | $39M | $9M | Operating incomeOp. inc. |
| 38.5% | −921.1% | −274.9% | −70.7% | −73.5% | −62.3% | −64.3% | 4.4% | 25.4% | 11.1% | 2.3% | Operating marginOp. mgn |
| $126M | ($117M) | ($87M) | ($52M) | ($57M) | ($81M) | ($87M) | ($10M) | $31M | $1M | — | Pretax incomePretax |
| $126M | ($117M) | ($87M) | ($52M) | ($57M) | ($81M) | ($87M) | ($12M) | $28M | $6M | ($44M) | Net incomeNet inc. |
| Cash flow & returns | |||||||||||
| ($78M) | ($65M) | ($38M) | ($88M) | ($28M) | ($62M) | ($81M) | $34M | $43M | $18M | ($8M) | Operating cash flowOp. cash |
| $2M | $2M | $3M | $972K | $2M | $2M | $3M | $5M | $7M | $12M | $21M | Depreciation & amortizationD&A |
| ($211M) | $46M | $40M | ($44M) | $20M | $5M | ($10M) | $24M | ($14M) | ($24M) | ($13M) | Working capital & otherWC & other |
| $1M | — | $354K | $3M | $801K | $11M | $8M | $42M | $10M | $5M | $10M | CapexCapex |
| 0.7% | — | 1.3% | 4.1% | 1.2% | 15.2% | 7.6% | 21.3% | 3.4% | 1.3% | 2.6% | Capex / revenueCapex/rev |
| ($79M) | — | ($38M) | ($89M) | ($29M) | ($64M) | ($84M) | $30M | $35M | $14M | ($18M) | Owner earningsOwner earn. |
| −45.3% | — | −136.7% | −141.9% | −44.4% | −84.4% | −84.2% | 14.9% | 12.3% | 3.9% | −4.6% | Owner earnings marginOE mgn |
| ($79M) | — | ($38M) | ($91M) | ($29M) | ($73M) | ($88M) | ($8M) | $33M | $14M | ($18M) | Free cash flowFCF |
| −45.3% | — | −136.7% | −144.4% | −44.4% | −97.0% | −88.5% | −4.2% | 11.5% | 3.9% | −4.6% | Free cash flow marginFCF mgn |
| — | — | — | — | — | — | $15M | — | — | $348M | $348M | AcquisitionsAcquis. |
| ($1M) | $17M | ($234K) | ($23M) | $15M | ($152M) | $5M | ($2M) | ($97M) | ($305M) | — | Investing cash flowInv. cash |
| $43M | $74M | $61M | $70M | $50M | $270M | $21M | $137M | ($137M) | $315M | — | Financing cash flowFin. cash |
| ($36M) | $25M | $23M | ($41M) | $37M | $57M | ($54M) | $169M | ($191M) | $29M | — | Change in cashΔ cash |
| Balance sheet | |||||||||||
| $23M | $44M | $71M | $50M | $67M | $204M | $171M | $295M | $197M | $171M | $111M | Cash & investmentsCash+inv |
| $302K | $3M | $4M | $4M | $4M | $5M | $17M | $15M | $12M | $38M | $43M | ReceivablesReceiv. |
| $2M | $3M | $4M | $4M | $5M | $7M | $22M | $29M | $28M | $35M | $44M | InventoryInvent. |
| $3M | $7M | $5M | $5M | $6M | $7M | $11M | $10M | $7M | $9M | $11M | Accounts payablePayables |
| ($630K) | ($2M) | $2M | $3M | $4M | $5M | $28M | $34M | $33M | $65M | $77M | Operating working capitalOper. WC |
| $77M | $57M | $82M | $61M | $79M | $219M | $235M | $373M | $268M | $292M | $246M | Current assetsCur. assets |
| $92M | $88M | $75M | $66M | $74M | $48M | $67M | $104M | $82M | $171M | $143M | Current liabilitiesCur. liab. |
| 0.8× | 0.7× | 1.1× | 0.9× | 1.1× | 4.5× | 3.5× | 3.6× | 3.3× | 1.7× | 1.7× | Current ratioCurr. ratio |
| $29M | $27M | $26M | $27M | $26M | $37M | $45M | $84M | $85M | $82M | — | Net PP&ENet PP&E |
| — | — | — | — | — | — | $2M | $2M | $2M | $68M | $68M | GoodwillGoodwill |
| $107M | $85M | $108M | $94M | $109M | $321M | $295M | $475M | $394M | $792M | $732M | Total assetsAssets |
| $28M | $24M | $102M | $119M | $122M | $281M | $273M | $269M | $36M | $355M | $319M | Total debtDebt |
| $5M | ($20M) | $31M | $69M | $55M | $77M | $103M | ($26M) | ($161M) | $183M | $208M | Net debt / (cash)Net debt |
| — | — | — | — | — | -3.1× | -4.3× | 0.6× | 6.1× | 2.8× | 0.3× | Interest coverageInt. cov. |
| $291M | $299M | $283M | $284M | $289M | $531M | $546M | $721M | $473M | $843M | — | Total liabilitiesTotal liab. |
| ($184M) | ($215M) | ($175M) | ($191M) | ($180M) | ($209M) | ($251M) | ($246M) | ($79M) | ($51M) | ($67M) | Shareholders’ equityEquity |
| 2.9% | 41.3% | 24.6% | 9.8% | 10.0% | 16.2% | 13.5% | 8.9% | 7.5% | 6.9% | 7.1% | Stock comp / revenueSBC/rev |
| Per share | |||||||||||
| 92.1M | 104M | 144M | 196M | 223M | 249M | 257M | 267M | 284M | 314M | 309M | Shares out (diluted)Shares |
| $1.90 | $0.11 | $0.19 | $0.32 | $0.29 | $0.30 | $0.39 | $0.75 | $1.01 | $1.11 | $1.27 | Revenue / shareRev/sh |
| $1.36 | $-1.13 | $-0.60 | $-0.27 | $-0.26 | $-0.32 | $-0.34 | $-0.04 | $0.10 | $0.02 | $-0.14 | EPS (diluted)EPS |
| $-0.86 | — | $-0.26 | $-0.46 | $-0.13 | $-0.26 | $-0.33 | $0.11 | $0.12 | $0.04 | $-0.06 | Owner earnings / shareOE/sh |
| $-0.86 | — | $-0.26 | $-0.47 | $-0.13 | $-0.29 | $-0.34 | $-0.03 | $0.12 | $0.04 | $-0.06 | Free cash flow / shareFCF/sh |
| $0.01 | — | $0.00 | $0.01 | $0.00 | $0.05 | $0.03 | $0.16 | $0.03 | $0.01 | $0.03 | Cap. spending / shareCapex/sh |
| $-1.99 | $-2.06 | $-1.21 | $-0.97 | $-0.81 | $-0.84 | $-0.97 | $-0.92 | $-0.28 | $-0.16 | $-0.22 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | −5.8%/yr | +30.6%/yr |
| EPS | −37.9%/yr | — |
| Capital spending / share | +1.8%/yr | +32.2%/yr |
The year, in the company's words
the filing →Verbatim from the 10-K's management discussion. Each sentence is shown only because its subject, direction, and stated figures check out against the filed numbers on this page. The words are the company's; the arithmetic is the record's.
- Royalty+25.2%
“Royalty revenue from UT increased by $25.8 million, or 25%, for the year ended December 31, 2025 compared to the prior year due to UT's increase in net revenue from sales of Tyvaso DPI.”
✓ figure matches the filed record
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cashEach year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned $6M of profit into $14M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $6M | $28M | ($12M) | ($87M) | ($81M) |
| Depreciation & amortizationnon-cash charge added back | +$12M | +$7M | +$5M | +$3M | +$2M |
| Stock-based compensationreal costnon-cash, but a real cost | +$24M | +$21M | +$18M | +$13M | +$12M |
| Working capital & othertiming of cash in and out, other non-cash items | −$24M | −$14M | +$24M | −$10M | +$5M |
| Cash from operations | $18M | $43M | $34M | ($81M) | ($62M) |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −$5M | −$7M | −$5M | −$3M | −$2M |
| Owner earnings | $14M | $35M | $30M | ($84M) | ($64M) |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | — | −$2M | −$38M | −$4M | −$9M |
| Free cash flow | $14M | $33M | ($8M) | ($88M) | ($73M) |
| Owner-earnings marginowner earnings ÷ revenue | 4% | 12% | 15% | -84% | -84% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $24M), owner earnings is nearer ($11M).
Much of fiscal 2025's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- AdequateOperating income $39M ÷ interest expense $14M
What this means
Comfortable in a normal year, but below the margin of safety Graham looked for. Worth checking how stable the coverage has been across a full cycle.
- How heavy is the debt, net of cash? $183M · 4.7× operating profitHeavy net debtCash $75M + ST investments $96M − debt $355M
What this means
Netting $171M of cash and short-term investments against $355M of debt leaves $183M owed, about 4.7× a year's operating profit (9.1× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 40 + DIO 481 − DPO 123 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Not enough dataIndustry peers: median -69%
What this means
The filing data didn't include the inputs for this check.
- Thin, recently turned positivelatest $14M = operating cash $18M − maintenance capex $5M; positive each of the last 3 years, after an earlier loss stretch (9-yr median -45%)Industry peers: median -34%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 4% of revenue this year, a -45% median across 9 years. Treating stock comp as the real expense it is (less $24M of SBC) leaves ($11M).
- Cash-backedCash from ops $18M ÷ net income $6M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.37×HarvestingCapex $5M ÷ depreciation & amortization as filed $12M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 6.9%The count is risingStock compensation $24M (fiscal 2025), 6.9% of revenue · no repurchases · diluted shares +22.2% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 0 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $349M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity NearCurrent ratio ≥ 2× · 1.70×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $355M vs $121M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 7 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $0.02/share (latest year $0.02), the averaged base the calculator's gate runs on, and book value is $-0.16/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 3 of 10
What this means
Lost money in 7 year(s), look at what happened there before trusting the average.
- Operating margin −386% → 14% (3-yr avg ends)
In the filing’s words The record and the words agree: the margin widened and the filing attributes the gain to its own pricing, not volume alone.
What this means
Through the cycle the operating margin widened — about −386% early to 14% lately, median −64% — pricing power intact or improving.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Worst year 2017 · −921.1% op. margin
What this means
Operations went underwater in 2017, understand why before trusting the good years.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Jun 30, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$111M
- Receivables$43M
- Inventory$44M
- Other current assets$47M
- Accounts payable$11M
- Other current liabilities$132M
From the company's latest filing.
Acquisitions & goodwill
from the balance sheet & the 10-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Beside that spending sits $4M of cumulative amortization of acquired intangibles charged against earnings since fiscal 2025 — the purchase price of past deals, expensed over time.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and amortization summed across the company's full tagged history, write-downs across the 10-year record, from the company's own filings.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Chief executive | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|---|
| 2021 | Michael E. Castagna | $4.0M | $7.3M | ($64M) |
| 2022 | Michael E. Castagna | $3.9M | $9.7M | ($84M) |
| 2023 | Michael E. Castagna | $7.1M | $97k | $30M |
| 2024 | Michael E. Castagna | $9.5M | $22.8M | $35M |
| 2025 | Michael E. Castagna | $9.3M | $752k | $14M |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership2.6%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$24M
The slice of the business handed to employees in shares in fiscal 2025, 6.9% of revenue, equal to 62.4% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| INVAInnoviva Inc. | $411M | 79%3y | 85.6% | 44% | 63% |
| ARDXArdelyx Inc. | $407M | 89% | -86.5% | -82% | -103% |
| ESPREsperion Therapeutics Inc. | $403M | — | -62.8% | -383%1y | -48% |
| PHARPharming Group N.V. | $376M | 89% | 6.9% | -3%3y | 14% |
| ARQTArcutis Biotherapeutics Inc. | $376M | 90% | -65.3% | -56% | -57% |
| MNKDMannKind Corporation | $349M | 72% | -62.3% | — | -45% |
| CRMDCorMedix Inc. | $312M | -12% | -1.6%2y | -202% | -30%2y |
| EOLSEvolus Inc. | $297M | 68% | -44.0% | -142% | -34% |
| Group median | — | 79% | -53.1% | — | -40% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what MannKind Corporation has delivered.
MannKind Corporation’s latest year shows negative owner earnings, the mark of a build-out: total capital spending outruns the cash the business throws off today. So the tool opens on the steady-state base (maintenance capex in place of the build-out spend), the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.
—
9.0% = the 4.65% 10-year Treasury (Aug 19, 2026) + 4.35 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.65%, as of Aug 19, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Free cash flow ($18M) on 322M shares outstanding, per the 10-Q cover, as of 2026-07-24; net debt $208M. The base opens on the steady-state figure (the latest year is negative on total capex mid-build-out); clear Steady-state to use the year as filed. Net of stock comp treats option pay as the expense it is. Capex ($10M) runs well above depreciation ($21M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about ($13M), the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← MMSI its page in the Manual MNR →
Industry order: ← MIRM the Pharmaceuticals chapter MRK →